


PHARMACEUTICAL 2021



Mirum Pharmaceuticals Inc. Rank 215 of 409





PHARMACEUTICAL 2021

Mirum Pharmaceuticals Inc. Rank 215 of 409



The relative strengths and weaknesses of Mirum Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirum Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 164% points. The greatest weakness of Mirum Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is -149%, being 206% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	236,350
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,462
Liabilities, Non-Current	2,656
Other Assets	3,221
Other Compr. Net Income	-46
Other Expenses	341
Other Liabilities	47,651
Other Net Income	1,367
Property and Equipment	1,293
Research and Development	81,605
Revenues	0
Selling, General and Administrative Expense	22,691

Output Variable	Value in 1000 USD
Assets	240,864
Liabilities	68,769
Expenses	104,637
Stockholders Equity	172,095
Net Income	-103,270
Comprehensive Net Income	-103,293
Economic Capital Ratio	-149%